FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602458591> ?p ?o ?g. }

• W2602458591 endingPage "112" @default.
• W2602458591 startingPage "101" @default.
• W2602458591 abstract "Additional risk minimisation measures (aRMMs) for medicinal products are necessary to address specific important safety issues which may not be practically achieved through routine risk management measures alone. The implementation and determination of effectiveness for aRMMs can be a challenge as it involves multiple stakeholders. It is therefore important to have concise objectives to avoid undue burden on patients, healthcare professionals and the healthcare system. The aim of this study was to examine how aRMMs are implemented and how effectiveness is assessed in the European Union (EU) using practical examples from Roche Products Limited in the United Kingdom (UK) (referred to as the ‘Company’). Three centrally authorised products were selected from the Company’s portfolio, each of which had aRMMs to address important safety concerns; specifically, teratogenicity, medication error and infections. The implementation of EU aRMMs, effectiveness checks and specific UK activities were analysed. Hard copy folders and electronic sites for Company aRMMs were used to assess process indicators. Periodic benefit-risk evaluation reports for specified time intervals and the Company safety database was used in checking safety outcomes for the selected products. For each product, the effectiveness of aRMMs was analysed based on specific process indicators and the subsequent safety outcomes. Literature searches were performed on scientific databases for the purposes of the broader study. The main process indicators in measuring effectiveness of Company aRMMs were distribution metrics for educational materials, assessment of awareness and clinical actions among healthcare professionals (HCPs). Case reports of pregnancy, medication errors and progressive multifocal leukoencephalopathy (PML) were the outcome indicators for Erivedge®▼, Kadcyla®▼ and MabThera® (the latter specifically in autoimmune indications: rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis) respectively. No pregnancy, one medication error and 10 confirmed PML cases were reported for Erivedge®▼, Kadcyla®▼ and MabThera® respectively. For the chosen products, a reasonable awareness of aRMMs amongst HCPs is a positive indicator of success in the use of educational materials. However, low response rates from surveys indicate that voluntary feedback may not always achieve the desired level of response in measuring effectiveness. There is a challenge in determining overall effectiveness of aRMMs due to a lack of defined success thresholds. Further regulatory guidance to outline the elements and desired outcomes of aRMMs will be useful for consistency in achieving successful outcomes." @default.
• W2602458591 created "2017-04-07" @default.
• W2602458591 creator A5053194483 @default.
• W2602458591 creator A5056738603 @default.
• W2602458591 creator A5059067407 @default.
• W2602458591 date "2017-03-29" @default.
• W2602458591 modified "2023-10-18" @default.
• W2602458591 title "Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder" @default.
• W2602458591 cites W1505489204 @default.
• W2602458591 cites W1529230314 @default.
• W2602458591 cites W1838731158 @default.
• W2602458591 cites W1972942750 @default.
• W2602458591 cites W1980211500 @default.
• W2602458591 cites W1983784388 @default.
• W2602458591 cites W2008291984 @default.
• W2602458591 cites W2017648122 @default.
• W2602458591 cites W2022006860 @default.
• W2602458591 cites W2033083142 @default.
• W2602458591 cites W2037366022 @default.
• W2602458591 cites W2055104385 @default.
• W2602458591 cites W2063372123 @default.
• W2602458591 cites W2069990327 @default.
• W2602458591 cites W2083489695 @default.
• W2602458591 cites W2085337571 @default.
• W2602458591 cites W2125451304 @default.
• W2602458591 cites W2146196731 @default.
• W2602458591 cites W2159900599 @default.
• W2602458591 cites W2165033558 @default.
• W2602458591 cites W21957739 @default.
• W2602458591 cites W2407293328 @default.
• W2602458591 cites W4300881350 @default.
• W2602458591 cites W2083985704 @default.
• W2602458591 doi "https://doi.org/10.1007/s40290-017-0184-8" @default.
• W2602458591 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5376384" @default.
• W2602458591 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28413313" @default.
• W2602458591 hasPublicationYear "2017" @default.
• W2602458591 type Work @default.
• W2602458591 sameAs 2602458591 @default.
• W2602458591 citedByCount "19" @default.
• W2602458591 countsByYear W26024585912018 @default.
• W2602458591 countsByYear W26024585912019 @default.
• W2602458591 countsByYear W26024585912020 @default.
• W2602458591 countsByYear W26024585912021 @default.
• W2602458591 countsByYear W26024585912022 @default.
• W2602458591 countsByYear W26024585912023 @default.
• W2602458591 crossrefType "journal-article" @default.
• W2602458591 hasAuthorship W2602458591A5053194483 @default.
• W2602458591 hasAuthorship W2602458591A5056738603 @default.
• W2602458591 hasAuthorship W2602458591A5059067407 @default.
• W2602458591 hasBestOaLocation W26024585911 @default.
• W2602458591 hasConcept C10138342 @default.
• W2602458591 hasConcept C105639569 @default.
• W2602458591 hasConcept C108759981 @default.
• W2602458591 hasConcept C112930515 @default.
• W2602458591 hasConcept C12174686 @default.
• W2602458591 hasConcept C127413603 @default.
• W2602458591 hasConcept C144133560 @default.
• W2602458591 hasConcept C160735492 @default.
• W2602458591 hasConcept C162324750 @default.
• W2602458591 hasConcept C21547014 @default.
• W2602458591 hasConcept C2777589142 @default.
• W2602458591 hasConcept C2780821815 @default.
• W2602458591 hasConcept C2910001868 @default.
• W2602458591 hasConcept C38652104 @default.
• W2602458591 hasConcept C41008148 @default.
• W2602458591 hasConcept C50522688 @default.
• W2602458591 hasConcept C60644358 @default.
• W2602458591 hasConcept C71924100 @default.
• W2602458591 hasConcept C86803240 @default.
• W2602458591 hasConceptScore W2602458591C10138342 @default.
• W2602458591 hasConceptScore W2602458591C105639569 @default.
• W2602458591 hasConceptScore W2602458591C108759981 @default.
• W2602458591 hasConceptScore W2602458591C112930515 @default.
• W2602458591 hasConceptScore W2602458591C12174686 @default.
• W2602458591 hasConceptScore W2602458591C127413603 @default.
• W2602458591 hasConceptScore W2602458591C144133560 @default.
• W2602458591 hasConceptScore W2602458591C160735492 @default.
• W2602458591 hasConceptScore W2602458591C162324750 @default.
• W2602458591 hasConceptScore W2602458591C21547014 @default.
• W2602458591 hasConceptScore W2602458591C2777589142 @default.
• W2602458591 hasConceptScore W2602458591C2780821815 @default.
• W2602458591 hasConceptScore W2602458591C2910001868 @default.
• W2602458591 hasConceptScore W2602458591C38652104 @default.
• W2602458591 hasConceptScore W2602458591C41008148 @default.
• W2602458591 hasConceptScore W2602458591C50522688 @default.
• W2602458591 hasConceptScore W2602458591C60644358 @default.
• W2602458591 hasConceptScore W2602458591C71924100 @default.
• W2602458591 hasConceptScore W2602458591C86803240 @default.
• W2602458591 hasFunder F4320309432 @default.
• W2602458591 hasIssue "2" @default.
• W2602458591 hasLocation W26024585911 @default.
• W2602458591 hasLocation W26024585912 @default.
• W2602458591 hasLocation W26024585913 @default.
• W2602458591 hasLocation W26024585914 @default.
• W2602458591 hasOpenAccess W2602458591 @default.
• W2602458591 hasPrimaryLocation W26024585911 @default.
• W2602458591 hasRelatedWork W1964166318 @default.
• W2602458591 hasRelatedWork W2088925337 @default.

• next